HEALTH

ReVive to be distributed at local pharmacies

BY Michael Johnsen

HOBOKEN, N.J. Bio Medical Research Limited is making a concentrated effort this spring in placing its ReVive product, approved by the Food and Drug Administration last summer, onto drug store shelves.

ReVive helps to soothe tired muscles and promotes muscle recovery using a clinically-proven technology called electronic muscle stimulation.

The portable product provides six different muscle conditioning and recovery programs to soothe upper and lower back, shoulder, calf and other muscle groups commonly aggravated by regular exercise or exertion, Patricia Smith, CEO of Bio Medical, noted. “ReVive provides consumers with the professional technology used by physical therapists in a single, easy-to-use consumer product designed specifically for today’s active consumers.”

Bio Medical was originally sold through retailers like Sports Authority, GNC and Bed, Bath and Beyond, but is now taking a more targeted approach through pharmacies like A&P’s pharmacy banners and online druggist drugstore.com.

The ReVive muscle wellness product is currently approved for purchase using flexible spending accounts, Bio Medical noted.

Bio Medical is also developing a new product for pain relief in June, which uses TENS technology.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Researchers discover specific probiotic strain significantly improves IBS symptoms

BY Michael Johnsen

CINCINNATI A review by researchers at Northwestern University and University of Michigan of the utility of probiotics in the treatment of irritable bowel syndrome found that Bifidobacterium infantis 35624 was the only probiotic strain out of 13 different individual strains or preparations reviewed to significantly improve symptoms of IBS, including abdominal pain, bloating and bowel movement difficulty.

The researchers reviewed 16 random-controlled-studies, evaluating the efficacy, safety and tolerability of probiotics in the treatment of IBS. With the exception of the Bifidobacterium infantis 35624 studies, researchers found the other trials did not use an appropriate study design and did not adequately report adverse events. The article was published on the American Journal of Gastroenterology Web site in advance of appearing in the publication’s April 2009 issue.

Irritable bowel syndrome affects 1-in-5 Americans and treatment options are limited. Darren Brenner, Division of Gastroenterology and Department of Internal Medicine, at Northwestern University and lead investigator of this study, hypothesized that alterations in gut microflora may contribute to the development of IBS symptoms, and believed these symptoms could be improved by probiotics.

“Probiotics are gaining popularity for the treatment of multiple gastrointestinal disorders, including IBS,” Brenner said. “After assessment of the methodological and statistical designs of these studies, B. infantis 35624 was the only probiotic that showed repeated efficacy.”

KelloggsDRSNhttp://www.centerstoregrowth.com

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

House of Representatives expected to pass Dextromethorphan Distribution Act of 2009

BY Michael Johnsen

WASHINGTON The House of Representatives Monday evening was scheduled to vote on the Dextromethorphan Distribution Act of 2009, a bill introduced March 3 by Reps. Fred Upton, R-Mich., and Rick Larsen, D-Wash., to restrict the distribution, possession and sale of unfinished bulk dextromethorphan to those entities vetted and approved by the Food and Drug Administration.

The bill is expected to significantly curtail the abuse of DXM, a common cough medicine ingredient, and is widely supported by the industry, including both the National Association of Chain Drug Stores and the Consumer Healthcare Products Association.

“When used in legitimate health care products and taken correctly, dextromethorphan is a highly-effective cough suppressant with very few side effects and a decades-long track record of safety,” stated NACDS president and CEO Steven Anderson in a statement released Monday in anticipation of the bill’s passage. “There is no need for the typical consumer to have access to unfinished bulk dextromethorphan. This bill will go a long way to help ensure that the only entities that can access unfinished bulk dextromethorphan are those with a legitimate need.”

CHPA president Linda Suydam noted earlier this month its support of keeping the raw, unfinished form of dextromethorphan out of teenagers hands.

“Only manufacturers, pharmacists and researchers have a legitimate need for access to this ingredient in its unfinished form, and we offer our complete support to this federal measure. We believe that it will help protect America’s youth from unscrupulous online pushers who knowingly provide kids with the raw form of this ingredient as a means to get high,” Suydam stated.

This is the third time the Dextromethorphan Distribution Act has been introduced in the U.S. Congress. It passed the U.S. House of Representatives twice, but failed to move forward before the close of both the 109th and 110th Congresses.  “We fervently hope that the third time’s the charm for this important measure to get passed into law and start protecting our nation’s children,” Suydam said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?